Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions
Open accessThe DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus (AAV) vectors are one of the most efficient in vivo gene delivery platforms. Over the past decade, clinical trials of AAV vector-mediated gene transfer led to some of the most exciting results in the field of gene therapy and, recently, to the market approval of an AAV-based drug in Europe. With clinical development, however, it became obvious that the host immune system represents an important obstacle to successful gene transfer with AAV vectors. In this review article, we will discuss the issue of cytotoxic T cell responses directed against the AAV capsid encountered on human studies. While over the past several years the field has acquired a tremendous amount of information on the interactions of AAV vectors with the immune system, a lot of questions are still unanswered. Novel concepts are emerging, such as the relationship between the total capsid dose and the T cell-mediated clearance of transduced cells, the potential role of innate immunity in vector immunogenicity highlighted in preclinical studies, and the cross talk between regulatory and effector T cells in the determination of the outcome of gene transfer. There is still a lot to learn about immune responses in AAV gene transfer, for example, it is not well understood what are the determinants of the kinetics of activation of T cells in response to vector administration, why not all subjects develop detrimental T cell responses following gene transfer, and whether the intervention strategies currently in use to block T cell-mediated clearance of transduced cells will be safe and effective for all gene therapy indications. Results from novel preclinical models and clinical studies will help to address these points and to reach the important goal of developing safe and effective gene therapy protocols to treat human diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Self-citationEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · cited 10×
“In particular, in the AAV8-FIX study vector administration resulted in the activation of capsid-specific CD8 T cells, with an increase in liver enzymes that required intervention with corticosteroids detected in four out of six subjects (9, 84) from the highdose cohort, who received 2× 1012 vg/kg of vector, ~8–9 weeks…”
BackgroundResultInfluentialSelf-citationHematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
Kaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60982-9 · Cited by 1,067
Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome
Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M. P., Baricordi, C., Dionisio, F., Calabria, A., Giannelli, S., Castiello, M. C., et al. (2013) · Science · doi:10.1126/science.1233151 · Cited by 1,025
Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
Self-citationAAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 4×
“In this study, upon AAV gene transfer to liver, two subjects developed transient elevation of liver enzymes and loss of FIX transgene expression around week 4 post vector delivery due to the immune rejection of transduced hepatocytes mediated by capsid-specific CD8 T cells (74).”
BackgroundMethodInfluentialSelf-citationDystrophin Immunity in Duchenne's Muscular Dystrophy
Mendell, J. R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000228 · Cited by 655 · cited 2×
“Vector-encoded transgene product may be recognized as a foreign antigen, especially if the recipient of gene transfer is not tolerant to the protein encoded by the vector, thus triggering immune responses that can result in production of transgene-specific neutralizing antibodies (40) or triggering of T cell responses…”
BackgroundMarks, W. J., Ostrem, J. L., Verhagen, L., Starr, P. A., Larson, P. S., Bakay, R. A., Taylor, R., Cahn-Weiner, D. A., Stoessl, A. J., Olanow, C. W., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70065-6 · Cited by 596
Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802866105 · Cited by 558
Induction of Immune Tolerance to Coagulation Factor IX Antigen by In Vivo Hepatic Gene Transfer
Mingozzi, F., Liu, Y.-L., Dobrzynski, E., Kaufhold, A., Liu, J. H., Wang, Y., Arruda, V. R., High, K. A., & Herzog, R. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16887 · Cited by 466 · cited 2×
“For example, preclinical studies of intramuscular delivery of AAV vectors suggest that this approach carries a higher risk of triggering immune responses to the transgene (42) compared to other tissues such as the liver (43), and that the underlying disease-causing mutation is a major determinant of the risk of develo…”
BackgroundSelf-citationJaski, B. E., Jessup, M. L., Mancini, D. M., Cappola, T. P., Pauly, D. F., Greenberg, B., Borow, K., Dittrich, H., Zsebo, K. M., & Hajjar, R. J. (2009) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2009.01.013 · Cited by 457
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
Christine, C. W., Starr, P. A., Larson, P. S., Eberling, J. L., Jagust, W. J., Hawkins, R. A., VanBrocklin, H. F., Wright, J. F., Bankiewicz, K. S., & Aminoff, M. J. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c29356 · Cited by 445
Gaudet, D., Méthot, J., Déry, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., et al. (2013) · Gene Therapy · doi:10.1038/gt.2012.43 · Cited by 404
Worgall, S., Sondhi, D., Hackett, N. R., Kosofsky, B., Kekatpure, M. V., Neyzi, N., Dyke, J. P., Ballon, D., Heier, L., Greenwald, B. M., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.022 · Cited by 402
Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors
Zaiss, A.-K., Liu, Q., Bowen, G. P., Wong, N. C. W., Bartlett, J. S., & Muruve, D. A. (2002) · Journal of Virology · doi:10.1128/jvi.76.9.4580-4590.2002 · Cited by 394
A viral assembly factor promotes AAV2 capsid formation in the nucleolus
Sonntag, F., Schmidt, K., & Kleinschmidt, J. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001673107 · Cited by 392
Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus
Duan, D., Yue, Y., Yan, Z., Yang, J., & Engelhardt, J. F. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8317 · Cited by 391 · cited 1×
“At the intracellular level, it has been shown that the capsid is substrate for ubiquitination (66, 67), and that proteasome inhibitors, or mutation of surface exposed tyrosine residues that normally undergo phosphorylation and ubiquitination, enhance transduction by enhancing nuclear uptake of virus (68, 69).”
BackgroundOvercoming Preexisting Humoral Immunity to AAV Using Capsid Decoys
Mingozzi, F., Anguela, X. M., Pavani, G., Chen, Y., Davidson, R. J., Hui, D. J., Yazicioglu, M., Elkouby, L., Hinderer, C. J., Faella, A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005795 · Cited by 355 · cited 3×
“While clearly this results in lower total amounts of capsid being administered, in the negative side it may render vectors more susceptible for antibody-mediated neutralization (73).”
BackgroundSelf-citationAdeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents
Calcedo, R., Morizono, H., Wang, L., McCarter, R., He, J., Jones, D., Batshaw, M. L., & Wilson, J. M. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.05107-11 · Cited by 345
Nathwani, A. C., Rosales, C., McIntosh, J., Rastegarlari, G., Nathwani, D., Raj, D., Nawathe, S., Waddington, S. N., Bronson, R., Jackson, S., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.274 · Cited by 345
Self-citationFlotte, T. R., Trapnell, B. C., Humphries, M., Carey, B., Calcedo, R., Rouhani, F., Campbell-Thompson, M., Yachnis, A. T., Sandhaus, R. A., McElvaney, N. G., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.053 · Cited by 335
Zhu, J., Huang, X., & Yang, Y. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37607 · Cited by 330
Jiang, H., Couto, L. B., Patarroyo-White, S., Liu, T., Nagy, D., Vargas, J. A., Zhou, S., Scallan, C. D., Sommer, J., Vijay, S., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017913 · Cited by 330 · cited 1×
“Experiments in primates in the context of liver gene transfer suggest that the capsid is still detectable by the immune system several weeks following administration (26), indicated by the fact that interruption of immunosuppression (IS) 8 weeks after gene transfer results in a spike in anti-AAV antibodies.”
BackgroundSelf-citationBrantly, M. L., Chulay, J. D., Wang, L., Mueller, C., Humphries, M., Spencer, L. T., Rouhani, F., Conlon, T. J., Calcedo, R., Betts, M. R., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904514106 · Cited by 327
Immune Responses to AAV in Clinical Trials
Mingozzi, F., & A. High, K. (2011) · Current Gene Therapy · doi:10.2174/156652311796150354 · Cited by 324
Self-citationLong-term follow-up after gene therapy for canavan disease
Leone, P., Shera, D., McPhee, S. W. J., Francis, J. S., Kolodny, E. H., Bilaniuk, L. T., Wang, D.-J., Assadi, M., Goldfarb, O., Goldman, H. W., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003454 · Cited by 307
Mingozzi, F., Meulenberg, J. J., Hui, D. J., Basner-Tschakarjan, E., Hasbrouck, N. C., Edmonson, S. A., Hutnick, N. A., Betts, M. R., Kastelein, J. J., Stroes, E. S., et al. (2009) · Blood · doi:10.1182/blood-2008-07-167510 · Cited by 295 · cited 2×
“In some cases, detection of capsid T cell activation in PBMC correlated with lack of transgene expression in vector injected muscle (89, 91); while in other studies the detection of capsid T cells in PBMC seemed to have no effect on transgene persistence (28).”
BackgroundResultSelf-citationMcIntosh, J., Lenting, P. J., Rosales, C., Lee, D., Rabbanian, S., Raj, D., Patel, N., Tuddenham, E. G. D., Christophe, O. D., McVey, J. H., et al. (2013) · Blood · doi:10.1182/blood-2012-10-462200 · Cited by 278 · cited 1×
“One is to use hyperactive variants of the therapeutic protein (104–106), or stronger promoter elements (107), or else codon-optimized transgenes (108, 109).”
BackgroundSelf-citationMingozzi, F., Hasbrouck, N. C., Basner-Tschakarjan, E., Edmonson, S. A., Hui, D. J., Sabatino, D. E., Zhou, S., Wright, J. F., Jiang, H., Pierce, G. F., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080093 · Cited by 254 · cited 6×
“These peptides, named Tregitopes, have been used to modulate CD8+ T cell responses to AAV, resulting in suppression of cytotoxic responses against AAVtransduced cells and expansion of Tregs in vitro.”
BackgroundInfluentialSelf-citationCpG-depleted adeno-associated virus vectors evade immune detection
Faust, S. M., Bell, P., Cutler, B. J., Ashley, S. N., Zhu, Y., Rabinowitz, J. E., & Wilson, J. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68205 · Cited by 254 · cited 1×
“Additionally, recently published results indicate that the removal of CpG from the vector genome may contribute to reduce the potential immunogenicity of the transgene product (36).”
BackgroundEllis, B. L., Hirsch, M. L., Barker, J. C., Connelly, J. P., Steininger, R. J., & Porteus, M. H. (2013) · Virology Journal · doi:10.1186/1743-422x-10-74 · Cited by 252 · cited 1×
“In vitro studies attempting to determine the half-life of the capsid in transduced cells have been largely unsuccessful in predicting the fate of the capsid, mainly because of the poor infectivity of most serotypes in cell lines (29).”
BackgroundIntracellular trafficking of adeno-associated viral vectors
Ding, W., Zhang, L., Yan, Z., & Engelhardt, J. F. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302527 · Cited by 251
Mendell, J. R., Rodino‐Klapac, L. R., Rosales, X. Q., Coley, B. D., Galloway, G., Lewis, S., Malik, V., Shilling, C., Byrne, B. J., Conlon, T., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22251 · Cited by 248
Martino, A. T., Suzuki, M., Markusic, D. M., Zolotukhin, I., Ryals, R. C., Moghimi, B., Ertl, H. C. J., Muruve, D. A., Lee, B., & Herzog, R. W. (2011) · Blood · doi:10.1182/blood-2010-10-314518 · Cited by 246
Humoral immune response to AAV
Calcedo, R., & Wilson, J. M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00341 · Cited by 243 · cited 1×
“These interactions occur at multiple levels, starting from the innate recognition of the vector capsid and DNA genome (23), to the development of humoral (24) and cellmediated adaptive responses to the capsid and/or the transgene product.”
BackgroundImmune responses to AAV in a phase I study for Canavan disease
McPhee, S. W. J., Janson, C. G., Li, C., Samulski, R. J., Camp, A. S., Francis, J., Shera, D., Lioutermann, L., Feely, M., Freese, A., et al. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.885 · Cited by 241
Yan, Z., Zak, R., Luxton, G. W. G., Ritchie, T. C., Bantel-Schaal, U., & Engelhardt, J. F. (2002) · Journal of Virology · doi:10.1128/jvi.76.5.2043-2053.2002 · Cited by 222
Hösel, M., Broxtermann, M., Janicki, H., Esser, K., Arzberger, S., Hartmann, P., Gillen, S., Kleeff, J., Stabenow, D., Odenthal, M., et al. (2012) · Hepatology · doi:10.1002/hep.24625 · Cited by 219
Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy
Haurigot, V., Marcó, S., Ribera, A., Garcia, M., Ruzo, A., Villacampa, P., Ayuso, E., Añor, S., Andaluz, A., Pineda, M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66778 · Cited by 215 · cited 1×
“While these results strongly support the safety of gene transfer to eye and brain, future studies will help to understand whether the immune privilege is maintained at all vector doses, especially given the fact that some AAV vector serotypes can escape the blood–brain barrier (103), thus resulting in systemic exposur…”
ResultSelf-citationStroes, E. S., Nierman, M. C., Meulenberg, J. J., Franssen, R., Twisk, J., Henny, C. P., Maas, M. M., Zwinderman, A. H., Ross, C., Aronica, E., et al. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.175620 · Cited by 209
Pien, G. C., Basner-Tschakarjan, E., Hui, D. J., Mentlik, A. N., Finn, J. D., Hasbrouck, N. C., Zhou, S., Murphy, S. L., Maus, M. V., Mingozzi, F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36891 · Cited by 192 · cited 5×
“This result is somewhat in contrast with previous data showing that empty capsids do flag transduced cells for T cell recognition (70).”
BackgroundMethodResultInfluentialSelf-citationComplement Is an Essential Component of the Immune Response to Adeno-Associated Virus Vectors
Zaiss, A. K., Cotter, M. J., White, L. R., Clark, S. A., Wong, N. C. W., Holers, V. M., Bartlett, J. S., & Muruve, D. A. (2008) · Journal of Virology · doi:10.1128/jvi.01990-07 · Cited by 177
Mueller, C., Chulay, J. D., Trapnell, B. C., Humphries, M., Carey, B., Sandhaus, R. A., McElvaney, N. G., Messina, L., Tang, Q., Rouhani, F. N., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70314 · Cited by 169
Gao, K., Li, M., Zhong, L., Su, Q., Li, J., Li, S., He, R., Zhang, Y., Hendricks, G., Wang, J., et al. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2013.9 · Cited by 165 · cited 1×
“The jury is still out on the role of empty capsids in gene transfer, with some reports suggesting that these particles are not immunogenic (72), others arguing that they are detrimental for transduction efficiency (112), and recent reports showing that they are beneficial in the presence of anti-AAV neutralizing antib…”
BackgroundFinn, J. D., Ozelo, M. C., Sabatino, D. E., Franck, H. W. G., Merricks, E. P., Crudele, J. M., Zhou, S., Kazazian, H. H., Lillicrap, D., Nichols, T. C., et al. (2010) · Blood · doi:10.1182/blood-2010-06-288001 · Cited by 157
Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer
Dobrzynski, E., Mingozzi, F., Liu, Y.-L., Bendo, E., Cao, O., Wang, L., & Herzog, R. W. (2004) · Blood · doi:10.1182/blood-2004-03-0847 · Cited by 135
Self-citationFields, P. A., Arruda, V. R., Armstrong, E., Chu, K., Mingozzi, F., Hagstrom, J. N., Herzog, R. W., & High, K. A. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0441 · Cited by 127 · cited 1×
“Vector-encoded transgene product may be recognized as a foreign antigen, especially if the recipient of gene transfer is not tolerant to the protein encoded by the vector, thus triggering immune responses that can result in production of transgene-specific neutralizing antibodies (40) or triggering of T cell responses…”
BackgroundSelf-citationImmune responses to AAV-vectors, the Glybera example from bench to bedside
Ferreira, V., Petry, H., & Salmon, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00082 · Cited by 120 · cited 1×
“, recombinant or plasma-derived factor IX (FIX) for hemophilia B patients] were enrolled (9, 48, 60, 61).”
BackgroundEffective gene therapy for haemophilic mice with pathogenic factor IX antibodies
Markusic, D. M., Hoffman, B. E., Perrin, G. Q., Nayak, S., Wang, X., LoDuca, P. A., High, K. A., & Herzog, R. W. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302859 · Cited by 116
Finn, J. D., Hui, D., Downey, H. D., Dunn, D., Pien, G. C., Mingozzi, F., Zhou, S., & High, K. A. (2010) · Molecular Therapy · doi:10.1038/mt.2009.257 · Cited by 115
Self-citationWang, L., Figueredo, J., Calcedo, R., Lin, J., & Wilson, J. M. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.001 · Cited by 113
Stieger, K., Le Meur, G., Lasne, F., Weber, M., Deschamps, J.-Y., Nivard, D., Mendes-Madeira, A., Provost, N., Martin, L., Moullier, P., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.12.001 · Cited by 110
Immunology of AAV-Mediated Gene Transfer in the Eye
Willett, K., & Bennett, J. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00261 · Cited by 105 · cited 1×
“GENE TRANSFER TO IMMUNOPRIVILEGED BODY SITES Adeno-associated virus vectors have been administered to humans in several eye- (95) and brain- (96–102) targeted gene transfer trials.”
BackgroundHyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice
Cantore, A., Nair, N., Della Valle, P., Di Matteo, M., Màtrai, J., Sanvito, F., Brombin, C., Di Serio, C., D'Angelo, A., Chuah, M., et al. (2012) · Blood · doi:10.1182/blood-2012-05-432591 · Cited by 101
Zhang, P., Sun, B., Osada, T., Rodriguiz, R., Yang, X. Y., Luo, X., Kemper, A. R., Clay, T. M., & Koeberl, D. D. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.063 · Cited by 88
Veron, P., Leborgne, C., Monteilhet, V., Boutin, S., Martin, S., Moullier, P., & Masurier, C. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200620 · Cited by 88 · cited 2×
“(82) conducted a similar survey for AAV1 in PBMCs from healthy donors.”
BackgroundEnhancing transduction of the liver by adeno-associated viral vectors
Nathwani, A. C., Cochrane, M., McIntosh, J., Ng, C. Y. C., Zhou, J., Gray, J. T., & Davidoff, A. M. (2009) · Gene Therapy · doi:10.1038/gt.2008.137 · Cited by 77
Unzu, C., Hervás-Stubbs, S., Sampedro, A., Mauleón, I., Mancheño, U., Alfaro, C., de Salamanca, R. E., Benito, A., Beattie, S. G., Petry, H., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-122 · Cited by 69 · cited 1×
“Recent reports show impaired transduction levels under IS with mycophenolate mofetil (113), others report a longer plasma half-life of vector in non-human primates receiving IS (114).”
BackgroundBoisgerault, F., Gross, D.-A., Ferrand, M., Poupiot, J., Darocha, S., Richard, I., & Galy, A. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.208 · Cited by 63
Adeno-associated virus capsid antigen presentation is dependent on endosomal escape
Li, C., He, Y., Nicolson, S., Hirsch, M., Weinberg, M. S., Zhang, P., Kafri, T., & Samulski, R. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66611 · Cited by 61
MyD88 Signaling in B Cells Regulates the Production of Th1-dependent Antibodies to AAV
Sudres, M., Ciré, S., Vasseur, V., Brault, L., Da Rocha, S., Boisgérault, F., Le Bec, C., Gross, D. A., Blouin, V., Ryffel, B., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.101 · Cited by 59
Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes
Hui, D. J., Basner-Tschakarjan, E., Chen, Y., Davidson, R. J., Buchlis, G., Yazicioglu, M., Pien, G. C., Finn, J. D., Haurigot, V., Tai, A., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.166 · Cited by 47
Self-citationVelazquez, V. M., Bowen, D. G., & Walker, C. M. (2009) · Blood · doi:10.1182/blood-2008-01-131375 · Cited by 46 · cited 1×
“Similarly, apoptosis of transgene reactive T cells in muscle has been documented in mice (94) and in humans (90), indicating that additional factors are involved in the modulation immunogenicity of vector and transgene other than the target organ alone.”
BackgroundRogers, G. L., Martino, A. T., Zolotukhin, I., Ertl, H. C., & Herzog, R. W. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-25 · Cited by 45
Wu, T.-L., Li, H., Faust, S. M., Chi, E., Zhou, S., Wright, F., High, K. A., & Ertl, H. C. (2014) · Molecular Therapy · doi:10.1038/mt.2013.218 · Cited by 38
Mycophenolate mofetil impairs transduction of single-stranded adeno-associated viral vectors
Montenegro-Miranda, P. S., Bloemendaal, L. T., Kunne, C., de Waart, D. R., & Bosma, P. J. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.222 · Cited by 35 · cited 1×
“Recent reports show impaired transduction levels under IS with mycophenolate mofetil (113), others report a longer plasma half-life of vector in non-human primates receiving IS (114).”
Background
Research works printed but not linked: 51
- Biffi, 2013, Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy, Science, 341, 1233158, 10.1126/science.1233158 · DOI · Paper page
- Cideciyan, 2008, Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics, Proc Natl Acad Sci U S A, 105, 15112, 10.1073/pnas.0807027105 · DOI · Paper page
- Aiuti, 2009, Gene therapy for immunodeficiency due to adenosine deaminase deficiency, N Engl J Med, 360, 447, 10.1056/NEJMoa0805817 · DOI · Paper page
- Naldini, 2011, Ex vivo gene transfer and correction for cell-based therapies, Nat Rev Genet, 12, 301, 10.1038/nrg2985 · DOI · Paper page
- Buning, 2013, Gene therapy enters the pharma market: the short story of a long journey, EMBO Mol Med, 5, 1, 10.1002/emmm.201202291 · DOI · Paper page
- Li, 2007, Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo, J Virol, 81, 7540, 10.1128/JVI.00529-07 · DOI · Paper page
- Li, 2007, Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes, Mol Ther, 15, 792, 10.1038/mt.sj.6300090 · doi:10.1038/mt.sj.6300090
- Martino, 2013, Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells, Blood, 121, 2224, 10.1182/blood-2012-10-460733 · DOI · Paper page
- Muzyczka, 2001, Parvoviridae: The Viruses and Their Replication
- Zhou, 1998, In vitro packaging of adeno-associated virus DNA, J Virol, 72, 3241, 10.1128/JVI.72.4.3241-3247.1998 · DOI · Paper page
- Atchison, 1965, Adenovirus-associated defective virus particles, Science, 149, 754, 10.1126/science.149.3685.754 · DOI · Paper page
- Arechavaleta-Velasco, 2008, Adverse reproductive outcomes in urban women with adeno-associated virus-2 infections in early pregnancy, Hum Reprod, 23, 29, 10.1093/humrep/dem360 · DOI
- Rogers, 2011, Innate immune responses to AAV Vectors, Front Microbiol, 2, 194, 10.3389/fmicb.2011.00194 · DOI · Paper page
- Zwart, 2009, An experimental test of the independent action hypothesis in virus-insect pathosystems, Proc Biol Sci, 276, 2233, 10.1098/rspb.2009.0064 · DOI
- Buchlis, 2012, Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer, Blood, 119, 3038, 10.1182/blood-2011-09-382317 · DOI · Paper page
- Niemeyer, 2009, Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy, Blood, 113, 797, 10.1182/blood-2008-10-181479 · DOI · Paper page
- Wang, 2005, Major role of local immune responses in antibody formation to factor IX in AAV gene transfer, Gene Ther, 12, 1453, 10.1038/sj.gt.3302539 · DOI
- Arruda, 2010, Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B, Blood, 115, 4678, 10.1182/blood-2009-12-261156 · DOI · Paper page
- Haurigot, 2010, Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogs, Mol Ther, 18, 1318, 10.1038/mt.2010.73 · DOI · Paper page
- Toromanoff, 2010, Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle, Mol Ther, 18, 151, 10.1038/mt.2009.251 · DOI · Paper page
- Sun, 2007, Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance, Am J Hum Genet, 81, 1042, 10.1086/522236 · DOI
- Annoni, 2013, Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic mice, EMBO Mol Med, 5, 1684, 10.1002/emmm.201302857 · DOI · Paper page
- Cao, 2007, Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer, Blood, 110, 1132, 10.1182/blood-2007-02-073304 · DOI · Paper page
- Martino, 2009, Tolerance induction to cytoplasmic beta-galactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicity, PLoS One, 4, e6376, 10.1371/journal.pone.0006376 · DOI · Paper page
- Follenzi, 2004, Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice, Blood, 103, 3700, 10.1182/blood-2003-09-3217 · DOI · Paper page
- Breous, 2011, Inflammation promotes the loss of adeno-associated virus-mediated transgene expression in mouse liver, Gastroenterology, 141, 348, 10.1053/j.gastro.2011.04.002 · DOI · Paper page
- Matzinger, 2002, The danger model: a renewed sense of self, Science, 296, 301, 10.1126/science.1071059 · DOI · Paper page
- He, 2013, Kinetics of adeno-associated virus serotype 2 (AAV2) and AAV8 capsid antigen presentation in vivo are identical, Hum Gene Ther, 24, 545, 10.1089/hum.2013.065 · DOI · Paper page
- Oliveira, 2013, Importance of TAP-independent processing pathways, Mol Immunol, 55, 113, 10.1016/j.molimm.2012.10.005 · DOI
- Li, 2012, Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia, Gene Ther, 19, 288, 10.1038/gt.2011.90 · DOI · Paper page
- Erles, 1999, Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV), J Med Virol, 59, 406, 10.1002/(SICI)1096-9071(199911)59:3406::AID-JMV223.0.CO;2-N · doi:10.1002/(sici)1096-9071(199911)59:3406::aid-jmv223.0.co;2-n
- Hui, 2012, Characterization of AAV T cell epitopes presented by splenocytes from normal human donors, Mol Ther ASGCT Annu Meet Abstr, 20, S557
- Gao, 2002, Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy, Proc Natl Acad Sci U S A, 99, 11854, 10.1073/pnas.182412299 · DOI · Paper page
- Basner-Tschakarjan, 2013, Cellular immune responses to vector in a gene therapy trial for hemophilia b using an AAV8 self-complementary factor IX vector, Blood Am Soc Hematol Annu Meet, 122, 21
- Flotte, 2005, Correlation between DNA transfer and cystic fibrosis airway epithelial cell correction after recombinant adeno-associated virus serotype 2 gene therapy, Hum Gene Ther, 16, 921, 10.1089/hum.2005.16.921 · DOI · Paper page
- Herson, 2012, A phase I trial of adeno-associated virus serotype 1-gamma-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C, Brain, 135, 483, 10.1093/brain/awr342 · DOI · Paper page
- Mendell, 2009, Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins, Ann Neurol, 66, 290, 10.1002/ana.21732 · DOI · Paper page
- Ozeri, 2012, Alpha-1 antitrypsin promotes semimature, IL-10-producing and readily migrating tolerogenic dendritic cells, J Immunol, 189, 146, 10.4049/jimmunol.1101340 · DOI
- Marks, 2010, Gene delivery of AAV2-neurturin for Parkinson’s disease: a double-blind, randomised, controlled trial, Lancet Neurol, 9, 1164, 10.1016/S1474-4422(10)70254-4 · DOI · Paper page
- Finn, 2012, The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy, Blood, 120, 4521, 10.1182/blood-2012-06-440123 · DOI · Paper page
- Siner, 2013, Minimal modification in the factor VIII B domain sequence ameliorates the murine hemophilia A phenotype, Blood, 121, 4396, 10.1182/blood-2012-10-464164 · DOI · Paper page
- Nair, 2014, Computationally designed liver-specific transcriptional modules and hyperactive factor IX improve hepatic gene therapy, Blood, 123, 3195, 10.1182/blood-2013-10-534032 · DOI · Paper page
- Ward, 2011, Codon optimization of human factor VIII cDNAs leads to high-level expression, Blood, 117, 798, 10.1182/blood-2010-05-282707 · DOI · Paper page
- Alé, 2014, Neurotoxicity induced by antineoplastic proteasome inhibitors, Neurotoxicology, 10.1016/j.neuro.2014.02.001 · DOI
- Wang, 2012, Successful regional delivery and long-term expression of a dystrophin gene in canine muscular dystrophy: a preclinical model for human therapies, Mol Ther, 20, 1501, 10.1038/mt.2012.111 · DOI · Paper page
- Finn, 2010, Rabbit anti-thymocyte globulin (rATG) administrated concomitantly with liver delivery of AAV2-hFIX can promote inhibitor formation in rhesus macaques, Blood, 116, 3765, 10.1182/blood.V116.21.3765.3765 · DOI
- De Groot, 2008, Activation of natural regulatory T cells by IgG Fc-derived peptide “Tregitopesâ€, Blood, 112, 3303, 10.1182/blood-2008-02-138073 · DOI · Paper page
- Cousens, 2013, Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes, J Diabetes Res, 2013, 621693, 10.1155/2013/621693 · DOI
- van der Marel, 2012, Adeno-associated virus mediated delivery of Tregitope 167 ameliorates experimental colitis, World J Gastroenterol, 18, 4288, 10.3748/wjg.v18.i32.4288 · DOI
- Britten, 2011, Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond, Cancer Immunol Immunother, 60, 15, 10.1007/s00262-010-0940-z · DOI
- Britten, 2013, Immunological monitoring to rationally guide AAV gene therapy, Front Immunol, 4, 273, 10.3389/fimmu.2013.00273 · DOI
Cited by
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362
“Additionally, unlike previous viral delivery strategies, rAAV does not contain any viral genes, therefore there will be no active viral gene expression to amplify the immune response [66].”
BackgroundDevelopment of an intein-mediated split-Cas9 system for gene therapy
Truong, D.-J. J., Kühner, K., Kühn, R., Werfel, S., Engelhardt, S., Wurst, W., & Ortiz, O. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv601 · Cited by 371
“adeno-associated virus (rAAV), due to their high infection efficiency and very low immune response (5).”
BackgroundUnraveling the complex story of immune responses to AAV vectors trial after trial.
Vandamme, C., Adjali, O., & Mingozzi, F. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.150 · Cited by 234
Self-citationAdeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery
Nidetz, N. F., McGee, M. C., Tse, L. V., Li, C., Cong, L., Li, Y., & Huang, W. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107453 · Cited by 174
Chemical modification of the adeno-associated virus capsid to improve gene delivery
Mével, M., Bouzelha, M., Leray, A., Pacouret, S., Guilbaud, M., Penaud-Budloo, M., Alvarez-Dorta, D., Dubreil, L., Gouin, S. G., Combal, J. P., et al. (2020) · Chemical Science · doi:10.1039/c9sc04189c · Cited by 92
Metadata
- Authors
- Basner-Tschakarjan, E., & Mingozzi, F.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2014-07-23
- Volume
- 5
- Pages
- 350-350
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2053755635
- Cited by
- 95
- References
- 71
- FWCI
- 5.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.